PUBLICACIONES

Conditional approval of oncology medicines in Europe (2017-2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
Source: Alberto Borobia Published on 2026-10-28
Conditional approval of oncology medicines in Europe (2017-2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
Source: Alberto Borobia Published on 2026-10-28
Conditional approval of oncology medicines in Europe (2017-2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
Source: Alberto Borobia Published on 2026-10-28
Conditional approval of oncology medicines in Europe (2017-2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
Source: Alberto Borobia Published on 2026-10-28
Conditional approval of oncology medicines in Europe (2017-2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
Source: Alberto Borobia Published on 2026-10-28
Conditional approval of oncology medicines in Europe (2017-2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
Source: Alberto Borobia Published on 2026-10-28
Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19
Source: Alberto Borobia Published on 2026-10-12
Limitations of VKORC1 rs9934438 as a Surrogate Marker for Vitamin K Antagonist Dose Adjustment
Source: Alberto Borobia Published on 2026-10-01
Age-related patterns in paediatric paracetamol poisoning: a retrospective cohort study, 2015-2025
Source: Alberto Borobia Published on 2026-09-24
Pre-emptive CYP2C19 genotyping and voriconazole exposure in pediatric hematology patients at risk of aspergillosis: an exploratory randomized pilot study with a cost-consequence analysis
Source: Alberto Borobia Published on 2026-08-05
Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial
Source: Alberto Borobia Published on 2026-08-03
Feasibility and safety profile of intranasal third-party allogeneic CD45RO+/RA- memory T cells: a phase I clinical trial (vRELEASE-I NCT06699758)
Source: Alberto Borobia Published on 2026-07-23
Integrating pharmacogenetic and clinical factors to predict the C0/D/W-based tacrolimus phenotype in kidney transplantation
Source: Alberto Borobia Published on 2026-06-01
Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission
Source: Alberto Borobia Published on 2026-05-26
MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics
Source: Alberto Borobia Published on 2026-05-21

Hospital Universitario La Paz

Servicio de Farmacología Clínica – UCICEC

Horario:

Lunes a Jueves 8.00-17.00

Viernes 8.00 - 15.00

Teléfono: 91 207 14 66

Fax: 91 207 13 84

Email: ucicec.hulp@salud.madrid.org